Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer

Zijia Huang,Lingyan Zhou,Hanrui Zheng,Mei Zhan

DOI: https://doi.org/10.1007/s11096-024-01721-1

IF: 2.305

2024-04-22

International Journal of Clinical Pharmacy

Abstract:Colorectal cancer is a significant health concern worldwide, with metastatic CRC (mCRC) presenting a particularly challenging prognosis. The FRESCO-2 trial highlighted the potential of fruquintinib in heavily pretreated mCRC patients.

pharmacology & pharmacy